<p>, /PRNewswire/ -- 隨着減肥藥市場競爭的逐漸加劇，博瑞醫藥（688166.SH）最新披露的 BGM0504 三期臨牀數據重新點燃了市場的關注。</p>
<p>在高血壓人羣中，平均體重減少 19.3%，腰圍減少 16.5 厘米，收縮壓降低 22.9 mmHg，尿酸降低 70.7 μmol/L，甘油三酯降低 33.6%，儘管體重下降，骨密度卻顯示出改善而非下降，高劑量組的停藥率為 0.7%。如果這些指標單獨出現，其重要性主要反映在療效提升上；然而，當多個參數在單一產品中同時實現時，這類療法的作用從單一的體重管理擴展到全面的代謝管理。</p>
<p>在這種背景下，之前被視為輔助角色的目標現在進入了核心聚光燈：GIP。</p>
<p>在過去十多年中，GLP-1 定義了減肥藥的商業模式——以體重減少為核心終點的高價值創新療法。隨着雙激動劑時代的推進，GIP 的角色正在發生轉變，從最初主要貢獻於耐受性調節的認知，演變為代謝結構調節中的關鍵變量。這一轉變的重要性不僅在於增加了另一個靶點，更在於與 GIP 激活相關的更廣泛的代謝效應。</p>
<p><strong>從單一終點到多參數協同</strong></p>
<p>從創新軌跡的角度來看，體重管理領域已經經歷了明顯的升級週期。</p>
<p>單靶點的 GLP-1 藥物，其核心價值主要體現在體重減輕和血糖控制上，而對血壓、脂質和其他參數的影響大多是次要的、伴隨的改善。隨後，雙激動劑將體重減輕幅度推向接近 20% 的範圍，並在某些代謝標誌物上擴展了益處，但整體市場定價仍然以體重減少和降低血糖作為主要終點。</p>
<p>在這種背景下，BGM0504 的獨特之處並不是在任何單一指標上的突破，而是多個終點的協調改善。</p>
<p>腰圍減少 16.5 厘米表明對內臟脂肪的直接影響——這是核心風險驅動因素——而不是僅限於體重的影響。收縮壓降低超過 20 mmHg，且目標達成率超過 90%，使得效果從 “附帶改善” 轉變為臨牀可操作的範圍。尿酸降低 70.7 μmol/L 和甘油三酯降低超過 30% 接近專門代謝療法通常見到的幅度。</p>
<p>更重要的是，在接近 20% 的體重減輕背景下，骨密度沒有下降而是增加，同時停藥率保持在低水平的 0.7%。這表明，改善的療效並不是以骨質流失或治療依從性降低為代價實現的。</p>
<p>當一款藥物能夠同時改善體重、血壓、血脂和尿酸時，它在多個慢性病人羣中展現了效果。</p>
<p><strong>從機制到差異化：GIP 的嶄露頭角</strong></p>
<p>如果 BGM0504 的三期臨牀數據代表了結果，那麼機制決定了這些結果是否可以解釋和持續。</p>
<p>在 GLP-1 通路中，體重減輕主要源於攝入控制，通過抑制食慾和延遲胃排空來實現。血壓、脂質譜和其他標誌物的改善在很大程度上是體重減少的次要結果。</p>
<p>相比之下，GIP 更像是代謝系統內的內在調節變量。GIP 受體在脂肪組織中高度表達。激活後，它調節脂肪組織的血流和炎症狀態，從而調節脂肪分佈。這個過程不僅影響體脂百分比，還通過增強胰島素敏感性推動多個參數的協調改善，包括血脂和血壓。</p>
<p>從 BGM0504 的三期數據中，可以清晰地觀察到與這一機制通路的相關性。腰圍減少 16.5 厘米表明對內臟脂肪的影響，這是一個關鍵的心代謝風險因素。甘油三酯減少 33.6%，伴隨 LDL-C 降低和 HDL-C 升高，顯示出脂質代謝的有利重塑。尿酸降低 70.7 μmol/L 可以視為優化代謝環境的協調結果。</p>
<p>在血壓方面，多種因素協同作用——包括減少脂肪炎症、改善胰島素抵抗和增強血管內皮功能——導致收縮壓降低超過 22.9 mmHg，合併高血壓患者的控制率達到 92.9%。這一特徵反映了整體的、代謝驅動的調節效應。</p>
<p>在脂質代謝水平上，GIP 改善胰島素敏感性並調節脂蛋白代謝，從而影響極低密度脂蛋白（VLDL）的肝臟合成和分泌，同時促進外周組織的甘油三酯清除。這導致甘油三酯減少 33.6% 和脂蛋白組成優化。尿酸代謝的變化在很大程度上反映了代謝級聯效應。在肥胖和胰島素抵抗中，腎臟尿酸排泄受損。通過改善胰島素敏感性、減少脂肪炎症和優化能量代謝，GIP 有助於恢復尿酸排泄的平衡。</p>
<p>骨代謝是 GIP 機制的一個獨特特徵，得到了確鑿的人類和機制證據的支持。例如，發表在《臨牀內分泌與代謝雜誌》上的一項研究表明，GIP 顯著抑制骨吸收，與胰島素無關。GIP 受體在成骨細胞中表達；其激活通過調節 RANKL/OPG 通路促進骨形成並抑制骨吸收，從而有助於骨重塑。此外，當與 GLP-1 結合時，GIP 還會產生附加效應。多項綜述已將 GIP 確定為腸 - 骨軸中的關鍵調節激素，介導餐後骨重塑期間的骨吸收抑制和骨形成調節。</p>
<p>在傳統的單靶 GLP-1 通路中，快速減重通常伴隨着骨礦密度的下降，研究表明，增加 GIP 可以抵消這一風險。因此，儘管體重顯著減少，但骨礦密度沒有下降，甚至出現改善趨勢，可以通過減少骨吸收、增強骨形成和優化代謝環境的組合來機制性解釋。這也為慢性疾病管理中雙靶治療的長期結構穩定性提供了機制支持。</p>
<p>總體而言，GIP 不僅僅是一個增強減重的輔助靶點。相反，它參與了多個維度的系統級調節，包括脂肪分佈、代謝交叉對話和組織穩態的維持。當這一通路有效激活時，治療的影響不再侷限於體重這一單一終點，而是擴展到更廣泛的代謝參數。這一轉變也為理解 BGM0504 在多個心臟代謝指標上同時改善提供了機制基礎。</p>
<p>BGM0504 的獨特之處在於它在設計階段故意增加了 GIP 的權重。根據《自然 - 科學報告》的一項出版物，其雙激動劑活性約為 tirzepatide 的三倍。這一差異不僅僅是 “更強的效力”；相反，在可比劑量水平下，BGM0504 似乎實現了更高的 GIP 受體結合和更有效的信號激活，實質性地增加了 GIP 對整體藥理學的貢獻。</p>
<p>在這一架構中，GLP-1 和 GIP 承擔着不同的角色：GLP-1 提供減重和血糖控制的基礎效應，而 GIP 則更多地貢獻於脂肪分佈調節、代謝交叉對話和耐受性優化。</p>
<p><strong>從產品到平台：GIP 準備推動新一波差異化</strong></p>
<p>一旦差異化從機制擴展到商業模式，類別層面的變化便開始顯現。在全球範圍內，體重管理領域正從單靶向方法轉向多靶向組合，同時擴展到多種製劑和給藥途徑。除了 GLP-1 和 GIP，口服選擇、澱粉酶、肌肉保護靶點和脂肪信號通路都成為了活躍的探索前沿。</p>
<p>在這一背景下，博瑞醫藥的戰略更接近於平台型方法。</p>
<p>圍繞 BGM0504，公司不僅加強了其機制中的 GIP 成分，還推進了多個平行項目和模式，包括 BGM0504 與澱粉酶、MSTN 環肽、ALK7 靶向 siRNA 以及幾種口服制劑的組合。目標是組建一個涵蓋脂肪組織、肌肉、骨代謝和多種給藥場景的系統能力。換句話説，論點不再僅僅是開發一種減重藥物，而是構建一個更廣泛的代謝調節平台。</p>
<p>這讓我們回到最初的問題：為什麼 BGM0504 能夠在多個終點上同時實現一致的改善？GIP 影響多個代謝通路。臨牀試驗表明，GLP-1/GIP 雙激動劑在體重、血糖控制、血壓、脂質代謝和尿酸水平等方面產生效果。GIP 正日益成為塑造這一領域下一階段差異化的關鍵變量。</p>
<p>來源：博瑞醫藥</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEyJk5ld3NJdGVtSWQ9Q041NTgwMiZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTIwMjA4UFJfTkVXU19VU1BSX19fX19DTjU1ODAy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEyJk5ld3NJdGVtSWQ9Q041NTgwMiZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTIwMjA4UFJfTkVXU19VU1BSX19fX19DTjU1ODAy"/></p>

博瑞醫藥

<p>博瑞醫藥的 BGM0504 三期臨牀試驗結果顯示顯著的體重減輕和多項代謝參數的改善，包括平均體重減少 19.3% 和收縮壓降低 22.9 mmHg。該藥物的療效超越了體重管理，表明 GIP 的角色從輔助因素轉變為代謝調節中的關鍵變量。這種綜合方法突顯了 BGM0504 同時應對多種慢性疾病的潛力，標誌着減肥藥市場的重大進展</p>

<p>, /PRNewswire/ -- As competition in the weight loss drug market progressively intensifies, the latest Phase III clinical data disclosed by BrightGene Bio-Medical (688166.SH) for BGM0504 has reignited market attention.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- 隨着減肥藥市場競爭的逐漸加劇，博瑞醫藥（688166.SH）最新披露的 BGM0504 三期臨牀數據重新點燃了市場的關注。</p>
</div><p>Mean weight reduction of 19.3%, waist circumference decrease of 16.5 cm, systolic blood pressure reduction of 22.9 mmHg in the hypertensive population, alongside uric acid reduction of 70.7 μmol/L, triglyceride reduction of 33.6%, bone mineral density showing improvement rather than decline despite weight loss, and a discontinuation rate of 0.7% in the high-dose group. If these metrics appeared individually, their significance would primarily reflect efficacy enhancement; however, when multiple parameters are simultaneously achieved in a single product, such therapies extend from singular weight management toward comprehensive metabolic management.</p>
<div class="lb-trans"><p>在高血壓人羣中，平均體重減少 19.3%，腰圍減少 16.5 厘米，收縮壓降低 22.9 mmHg，尿酸降低 70.7 μmol/L，甘油三酯降低 33.6%，儘管體重下降，骨密度卻顯示出改善而非下降，高劑量組的停藥率為 0.7%。如果這些指標單獨出現，其重要性主要反映在療效提升上；然而，當多個參數在單一產品中同時實現時，這類療法的作用從單一的體重管理擴展到全面的代謝管理。</p>
</div><p>Against this backdrop, a target previously regarded largely as a supporting player is now entering the core spotlight: GIP.</p>
<div class="lb-trans"><p>在這種背景下，之前被視為輔助角色的目標現在進入了核心聚光燈：GIP。</p>
</div><p>Over the past decade-plus, GLP-1 has defined the business model for weight loss drugs—high-value innovative therapeutics driven by weight reduction as the core endpoint. As the dual-agonist era advances, the role of GIP is undergoing transformation, evolving from its early perception as primarily contributing to tolerability modulation toward becoming a critical variable in metabolic architecture regulation. The significance of this shift lies not merely in adding another target, but in the broader metabolic effects associated with GIP activation.</p>
<div class="lb-trans"><p>在過去十多年中，GLP-1 定義了減肥藥的商業模式——以體重減少為核心終點的高價值創新療法。隨着雙激動劑時代的推進，GIP 的角色正在發生轉變，從最初主要貢獻於耐受性調節的認知，演變為代謝結構調節中的關鍵變量。這一轉變的重要性不僅在於增加了另一個靶點，更在於與 GIP 激活相關的更廣泛的代謝效應。</p>
</div><p><strong>From a Single Endpoint to Multi-Parameter Synergy</strong></p>
<div class="lb-trans"><p><strong>從單一終點到多參數協同</strong></p>
</div><p>From an innovation trajectory standpoint, the weight-management space has already undergone a clear upgrade cycle.</p>
<div class="lb-trans"><p>從創新軌跡的角度來看，體重管理領域已經經歷了明顯的升級週期。</p>
</div><p>Single-target GLP-1 drugs, with its core value primarily reflected in weight loss and glycemic control, while effects on blood pressure, lipids, and other parameters have largely been secondary, accompanying improvements. Subsequently, dual agonists pushed weight loss magnitude closer to the ~20% range and extended benefits across certain metabolic markers, but overall market pricing has still been anchored to weight reduction and glucose lowering as the primary endpoints.</p>
<div class="lb-trans"><p>單靶點的 GLP-1 藥物，其核心價值主要體現在體重減輕和血糖控制上，而對血壓、脂質和其他參數的影響大多是次要的、伴隨的改善。隨後，雙激動劑將體重減輕幅度推向接近 20% 的範圍，並在某些代謝標誌物上擴展了益處，但整體市場定價仍然以體重減少和降低血糖作為主要終點。</p>
</div><p>Against this backdrop, BGM0504's distinguishing feature is not a breakthrough in any single metric, but rather the coordinated improvement across multiple endpoints.</p>
<div class="lb-trans"><p>在這種背景下，BGM0504 的獨特之處並不是在任何單一指標上的突破，而是多個終點的協調改善。</p>
</div><p>A 16.5 cm reduction in waist circumference suggests a direct impact on visceral fat—a core risk driver—rather than an effect limited to body weight alone. A blood pressure reduction of more than 20 mmHg, together with a target achievement rate above 90%, moves the effect from &#34;ancillary improvement&#34; into a clinically actionable range. A 70.7 μmol/L decrease in uric acid and a triglyceride reduction of more than 30% are approaching the magnitude typically seen with dedicated metabolic therapies.</p>
<div class="lb-trans"><p>腰圍減少 16.5 厘米表明對內臟脂肪的直接影響——這是核心風險驅動因素——而不是僅限於體重的影響。收縮壓降低超過 20 mmHg，且目標達成率超過 90%，使得效果從 “附帶改善” 轉變為臨牀可操作的範圍。尿酸降低 70.7 μmol/L 和甘油三酯降低超過 30% 接近專門代謝療法通常見到的幅度。</p>
</div><p>More importantly, in the context of nearly 20% weight loss, bone mineral density did not decline but instead increased, while the discontinuation rate remained at a low 0.7%. This indicates that improved efficacy was not achieved at the expense of bone loss or reduced treatment adherence.</p>
<div class="lb-trans"><p>更重要的是，在接近 20% 的體重減輕背景下，骨密度沒有下降而是增加，同時停藥率保持在低水平的 0.7%。這表明，改善的療效並不是以骨質流失或治療依從性降低為代價實現的。</p>
</div><p>When a single drug can simultaneously improve body weight, blood pressure, blood lipids and uric acid, it demonstrates effects across multiple chronic disease populations.</p>
<div class="lb-trans"><p>當一款藥物能夠同時改善體重、血壓、血脂和尿酸時，它在多個慢性病人羣中展現了效果。</p>
</div><p><strong>From Mechanism to Differentiation: The Emerging Role of GIP</strong></p>
<div class="lb-trans"><p><strong>從機制到差異化：GIP 的嶄露頭角</strong></p>
</div><p>If the Phase III clinical data of BGM0504 represent the outcomes, the mechanism determines whether these outcomes are explainable and sustainable.</p>
<div class="lb-trans"><p>如果 BGM0504 的三期臨牀數據代表了結果，那麼機制決定了這些結果是否可以解釋和持續。</p>
</div><p>Within the GLP–1 pathway, weight loss primarily stems from intake control, achieved via appetite suppression and delayed gastric emptying. Improvements in blood pressure, lipid profile, and other markers are largely secondary consequences of weight reduction.</p>
<div class="lb-trans"><p>在 GLP-1 通路中，體重減輕主要源於攝入控制，通過抑制食慾和延遲胃排空來實現。血壓、脂質譜和其他標誌物的改善在很大程度上是體重減少的次要結果。</p>
</div><p>In contrast, GIP acts more as an intrinsic regulatory variable within the metabolic system. The GIP receptor is highly expressed in adipose tissue. Upon activation, it modulates adipose tissue blood flow and inflammatory status, thereby regulating fat distribution. This process not only affects body fat percentage but also drives coordinated improvements across multiple parameters—including blood lipids and blood pressure—by enhancing insulin sensitivity.</p>
<div class="lb-trans"><p>相比之下，GIP 更像是代謝系統內的內在調節變量。GIP 受體在脂肪組織中高度表達。激活後，它調節脂肪組織的血流和炎症狀態，從而調節脂肪分佈。這個過程不僅影響體脂百分比，還通過增強胰島素敏感性推動多個參數的協調改善，包括血脂和血壓。</p>
</div><p>From the Phase III data of BGM0504, a clear correlation can be observed with this mechanistic pathway. A 16.5 cm reduction in waist circumference indicates an impact on visceral fat, a key cardiometabolic risk factor. A 33.6% decrease in triglycerides, along with reduced LDL–C and elevated HDL–C, demonstrates favorable remodeling of lipid metabolism. A 70.7 μmol/L reduction in uric acid can be regarded as a coordinated outcome of an optimized metabolic milieu.</p>
<div class="lb-trans"><p>從 BGM0504 的三期數據中，可以清晰地觀察到與這一機制通路的相關性。腰圍減少 16.5 厘米表明對內臟脂肪的影響，這是一個關鍵的心代謝風險因素。甘油三酯減少 33.6%，伴隨 LDL-C 降低和 HDL-C 升高，顯示出脂質代謝的有利重塑。尿酸降低 70.7 μmol/L 可以視為優化代謝環境的協調結果。</p>
</div><p>For blood pressure, multiple factors act in concert—including reduced adipose inflammation, improved insulin resistance, and enhanced vascular endothelial function—leading to a systolic blood pressure reduction of over 22.9 mmHg and a 92.9% control rate in patients with concomitant hypertension. This profile reflects a holistic, metabolism–driven regulatory effect.</p>
<div class="lb-trans"><p>在血壓方面，多種因素協同作用——包括減少脂肪炎症、改善胰島素抵抗和增強血管內皮功能——導致收縮壓降低超過 22.9 mmHg，合併高血壓患者的控制率達到 92.9%。這一特徵反映了整體的、代謝驅動的調節效應。</p>
</div><p>At the lipid metabolism level, GIP improves insulin sensitivity and modulates lipoprotein metabolism, thereby affecting hepatic synthesis and secretion of very-low-density lipoprotein (VLDL) while promoting triglyceride clearance in peripheral tissues. This results in a 33.6% reduction in triglycerides and optimized lipoprotein composition. Changes in uric acid metabolism largely reflect a metabolic cascade effect. In obesity and insulin resistance, renal uric acid excretion is impaired. By improving insulin sensitivity, reducing adipose inflammation, and optimizing energy metabolism, GIP helps restore uric acid excretion balance.</p>
<div class="lb-trans"><p>在脂質代謝水平上，GIP 改善胰島素敏感性並調節脂蛋白代謝，從而影響極低密度脂蛋白（VLDL）的肝臟合成和分泌，同時促進外周組織的甘油三酯清除。這導致甘油三酯減少 33.6% 和脂蛋白組成優化。尿酸代謝的變化在很大程度上反映了代謝級聯效應。在肥胖和胰島素抵抗中，腎臟尿酸排泄受損。通過改善胰島素敏感性、減少脂肪炎症和優化能量代謝，GIP 有助於恢復尿酸排泄的平衡。</p>
</div><p>Bone metabolism represents a distinctive feature of the GIP mechanism, supported by established human and mechanistic evidence. For instance, a study published in the <em>Journal of Clinical Endocrinology &amp; Metabolism</em> demonstrated that GIP significantly inhibits bone resorption independently of insulin. GIP receptors are expressed in osteoblasts; their activation promotes bone formation and suppresses bone resorption via regulation of the RANKL/OPG pathway, thereby contributing to bone remodeling. Moreover, GIP exerts additive effects when combined with GLP-1. Multiple reviews have identified GIP as a key regulatory hormone in the gut–bone axis, mediating both bone resorption inhibition and bone formation modulation during postprandial bone remodeling.</p>
<div class="lb-trans"><p>骨代謝是 GIP 機制的一個獨特特徵，得到了確鑿的人類和機制證據的支持。例如，發表在《臨牀內分泌與代謝雜誌》上的一項研究表明，GIP 顯著抑制骨吸收，與胰島素無關。GIP 受體在成骨細胞中表達；其激活通過調節 RANKL/OPG 通路促進骨形成並抑制骨吸收，從而有助於骨重塑。此外，當與 GLP-1 結合時，GIP 還會產生附加效應。多項綜述已將 GIP 確定為腸 - 骨軸中的關鍵調節激素，介導餐後骨重塑期間的骨吸收抑制和骨形成調節。</p>
</div><p>Along the traditional single-target GLP-1 pathway, rapid weight loss is often accompanied by declines in bone mineral density, and studies show that the addition of GIP offsets this risk. Accordingly, the absence of bone mineral density loss—and even an improving trend—despite substantial weight reduction can be mechanistically explained by a combination of reduced bone resorption, enhanced bone formation, and an optimized metabolic milieu. This also provides mechanistic support for the long-term structural stability of dual-target therapies in chronic disease management.</p>
<div class="lb-trans"><p>在傳統的單靶 GLP-1 通路中，快速減重通常伴隨着骨礦密度的下降，研究表明，增加 GIP 可以抵消這一風險。因此，儘管體重顯著減少，但骨礦密度沒有下降，甚至出現改善趨勢，可以通過減少骨吸收、增強骨形成和優化代謝環境的組合來機制性解釋。這也為慢性疾病管理中雙靶治療的長期結構穩定性提供了機制支持。</p>
</div><p>Overall, GIP is not merely an auxiliary target that amplifies weight loss. Rather, it participates in system-level regulation across multiple dimensions, including fat distribution, metabolic cross-talk, and maintenance of tissue homeostasis. When this pathway is effectively activated, a therapy's impact is no longer confined to the single endpoint of body weight, but extends across a broader set of metabolic parameters. This shift also offers a mechanistic basis for understanding BGM0504's concurrent improvements across multiple cardiometabolic indicators.</p>
<div class="lb-trans"><p>總體而言，GIP 不僅僅是一個增強減重的輔助靶點。相反，它參與了多個維度的系統級調節，包括脂肪分佈、代謝交叉對話和組織穩態的維持。當這一通路有效激活時，治療的影響不再侷限於體重這一單一終點，而是擴展到更廣泛的代謝參數。這一轉變也為理解 BGM0504 在多個心臟代謝指標上同時改善提供了機制基礎。</p>
</div><p>BGM0504 is distinctive in that it deliberately increased the weighting of GIP at the design stage. According to a <em>Nature - Scientific Reports</em> publication, its dual-agonist activity is approximately three times that of tirzepatide. This difference is not merely a matter of &#34;stronger potency&#34;; rather, at comparable dose levels, BGM0504 appears to achieve higher GIP receptor engagement and more efficient signaling activation, materially increasing GIP's contribution to the overall pharmacology.</p>
<div class="lb-trans"><p>BGM0504 的獨特之處在於它在設計階段故意增加了 GIP 的權重。根據《自然 - 科學報告》的一項出版物，其雙激動劑活性約為 tirzepatide 的三倍。這一差異不僅僅是 “更強的效力”；相反，在可比劑量水平下，BGM0504 似乎實現了更高的 GIP 受體結合和更有效的信號激活，實質性地增加了 GIP 對整體藥理學的貢獻。</p>
</div><p>Within this architecture, GLP-1 and GIP take on differentiated roles: GLP-1 provides the foundational effects on weight reduction and glycemic control, while GIP contributes more to fat distribution modulation, metabolic cross-talk, and tolerability optimization.</p>
<div class="lb-trans"><p>在這一架構中，GLP-1 和 GIP 承擔着不同的角色：GLP-1 提供減重和血糖控制的基礎效應，而 GIP 則更多地貢獻於脂肪分佈調節、代謝交叉對話和耐受性優化。</p>
</div><p><strong>From Product to Platform: GIP Is Poised to Drive a New Wave of Differentiation</strong></p>
<div class="lb-trans"><p><strong>從產品到平台：GIP 準備推動新一波差異化</strong></p>
</div><p>Once differentiation extends from mechanism into business model, shifts at the category level begin to emerge. Globally, the weight-management field is moving from single-target approaches toward multi-target combinations, along with expansion into multiple formulations and routes of administration. Beyond GLP-1 and GIP, oral options, amylin, muscle-preservation targets, and adipose signaling pathways are all becoming active frontiers of exploration.</p>
<div class="lb-trans"><p>一旦差異化從機制擴展到商業模式，類別層面的變化便開始顯現。在全球範圍內，體重管理領域正從單靶向方法轉向多靶向組合，同時擴展到多種製劑和給藥途徑。除了 GLP-1 和 GIP，口服選擇、澱粉酶、肌肉保護靶點和脂肪信號通路都成為了活躍的探索前沿。</p>
</div><p>In this landscape, BrightGene Bio-Medical's strategy is closer to a platform-based approach.</p>
<div class="lb-trans"><p>在這一背景下，博瑞醫藥的戰略更接近於平台型方法。</p>
</div><p>Building around BGM0504, the company has not only strengthened the GIP component of its mechanism, but has also advanced multiple parallel programs and modalities, including combinations of BGM0504 with amylin, an MSTN cyclic peptide, an ALK7-targeting siRNA, and several oral formulations. The goal is to assemble a systematic set of capabilities spanning adipose tissue, muscle, bone metabolism, and diverse dosing scenarios. In other words, the thesis is no longer simply to develop a single weight-loss drug, but to build a broader metabolic regulation platform.</p>
<div class="lb-trans"><p>圍繞 BGM0504，公司不僅加強了其機制中的 GIP 成分，還推進了多個平行項目和模式，包括 BGM0504 與澱粉酶、MSTN 環肽、ALK7 靶向 siRNA 以及幾種口服制劑的組合。目標是組建一個涵蓋脂肪組織、肌肉、骨代謝和多種給藥場景的系統能力。換句話説，論點不再僅僅是開發一種減重藥物，而是構建一個更廣泛的代謝調節平台。</p>
</div><p>This brings us back to the original question: why was BGM0504 able to deliver consistent improvements across multiple endpoints at the same time? GIP affects multiple metabolic pathways. Clinical trials show that GLP-1/GIP dual agonists produce effects across body weight, glycemic control, blood pressure, lipid metabolism, and uric acid levels. GIP is increasingly emerging as a key variable shaping the next phase of differentiation in this space.</p>
<div class="lb-trans"><p>這讓我們回到最初的問題：為什麼 BGM0504 能夠在多個終點上同時實現一致的改善？GIP 影響多個代謝通路。臨牀試驗表明，GLP-1/GIP 雙激動劑在體重、血糖控制、血壓、脂質代謝和尿酸水平等方面產生效果。GIP 正日益成為塑造這一領域下一階段差異化的關鍵變量。</p>
</div><p>SOURCE BrightGene</p>
<div class="lb-trans"><p>來源：博瑞醫藥</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEyJk5ld3NJdGVtSWQ9Q041NTgwMiZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTIwMjA4UFJfTkVXU19VU1BSX19fX19DTjU1ODAy" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN55802&amp;Transmission_Id=202605120208PR_NEWS_USPR_____CN55802&amp;DateId=20260512"/></p>

02:08 ETGIP 從輔助角色轉變為關鍵變量：博瑞醫藥的 III 期結果顯示其在減重領域的差異化